

INVITATION
(prepared in accordance to article 121 par. 4 of Law 4548/2018)
OF THE SHAREHOLDERS OF THE COMPANY WITH THE NAME
"AUTOMATIC ANALYZERS - DIAGNOSTIC REAGENTS AND PRIVATE DIAGNOSTIC
LABORATORIES MEDICON HELLAS SA"
No. G.E.MI 414401000
(former No. M.A.E. 16439/06/B/88/24)

TO THE ANNUAL ORDINARY GENERAL MEETING ON 26TH JUNE 2023

The Board of Directors of the Company under the name "AUTOMATIC ANALYZERS - DIAGNOSTIC REAGENTS AND PRIVATE DIAGNOSTIC LABORATORIES MEDICON HELLAS S.A", invites in accordance to the Law and the Articles of Association, the shareholders of the Company to the Annual General Meeting, which will be held on the twenty-sixth (26th) of June 2023, Monday at 3:00 p.m., at the Company's headquarters (Melitona 5–7, Gerakas Attica, 1st floor), to discuss and decide on the following daily agenda:

SUBJECTS OF THE DAILY AGENDA

- 1] Submission and approval of the Annual Financial Statements (Corporate and Consolidated) of MEDICON HELLAS A.E. fiscal year 2022 (01.01.2022–31.12.2022), after the submission, hearing and approval of the Annual Report of the Board of Directors and the auditor's Audit Report.
- 2] Approval of profit allocation for the period 01.01.2022–31.12.2022.
- 3] Approval of the overall management of the Board of Directors for the corporate year 01.01.2022-31.12.2022 according to article 108 of Law 4548/2018 and exemption of the Company's Auditors from any responsibility of reimbursement for the corporate year 2022, as well as for the Annual Financial Statements of the year 2022 according to article 117 par. 1 c. of Law 4548/2018.
- 4] Submission for discussion and voting by the Annual General Meeting of the Remuneration Report for the corporate year 01.01.2022-31.12.2022 in accordance with article 112 of Law 4548/2018, as applicable.
- 5] Approval of the payments, salaries and compensations of the members of the Company's Board of Directors, the Audit Committee and the Executives for the corporate year 01.01.2022-31.12.2022 according to article 109 of Law 4548/2018.
- 6] Approval of contracts, approval and pre-approval and determination of salaries, fees and compensations paid during the 2023-2024 financial years to the members of the

Board of Directors, the Audit Committee and the Executives as well as granting permission for advance payment of the remuneration to these members, for the period of time until the next Ordinary General Meeting in accordance to articles 109 and 117 of Law 4548/2018.

7] Provision of approval - permission to enter into employment contracts or mandates of the company with members of its Board of Directors and setting an upper limit of their salaries.

8] Submission and presentation of the audit committee's annual report for the 2022 financial year (01.01.2022-31.12.2022).

9] Election of an Audit Company for the Regular Audit of the Financial Statements (Corporate and consolidated) of MEDICON HELLAS A.E., in accordance with the International Financial Reporting Standards, of the management period 01.01.2023 - 31.12.2023 and determination of its salary figure.

10] Provision of permission in accordance with article 98 par. 1 of Law 4548/2018, as applicable, to the members of the Board of Directors and the managers of the Company to participate in Boards of Directors or in the management of the subsidiaries, relatives and associated companies of the Group, which pursue similar and/or related purposes.

11] Submission to the General Assembly, of the Report of the Independent Non-Executive Members of the Board of Directors in accordance with article 9 par. 5 of Law 4706/2020 as applicable.

12] Announcement of the election of a new member of the Board of Directors to replace a resigned one. Decision on the appointment or election of a new member until the end of the term of office of the above resigned member.

13] Various issues and announcements.

A. THE RIGHT TO VOTE AND PARTICIPATE

Every ordinary share grants the right of one (1) vote. At the Annual General Meeting, any shareholder has the right participate, as long as they are registered at the records of Dematerialized Securities System (D.S.S) under the name HELLENIC CENTRAL SECURITIES DEPOSITORY S.A, at which the company's shares are held, or the person identified as such on the basis of the relevant date though registered intermediaries or other intermediaries subject to the provisions of the legislation law (Law 4548/2018, Law 4569/2018, Law

4706/2020 and Regulation (EU) 2018/23012) as well as the Regulation of Operation of the Hellenic Central Securities Depository (Government Gazette B'1007/16.03.2021).

The status of the shareholder must be valid until the **21st.06.2023 (registration date)**, at the commencement of the fifth day (5th) before the day of the Annual General Meeting on the 26th .06.2023. The proof for the shareholder's capacity can be obtained by any legal means and will be based on the information that the company receives from the central repository of titles, as long as they provide register services or through the participants and registered intermediaries at the Central Repository of titles in any other case. From the company's behalf, the participation and voting right for the Annual General Meeting is granted only to the shareholders that have a valid capacity at the date of the register. It is noted, that the exercise of such rights (participation and voting) does not have as a prerequisite neither the binding of the shareholders' shares or the abide of any other relevant procedure, that may restrict the possibility to sell and transfer those shares for the timeframe between the date of the register and the date of the Annual General Meeting.

B. THE RIGHTS OF THE MINORITY OF SHAREHOLDERS

(a) With an application from the shareholders representing the one twentieth (1/20) of the paid – up shared capital, the company's Board of Directors is obligated to include at the daily agenda of the Annual General Meeting any additional subjects, if the relevant application arrives at the Board of Directors until the **11th.06.2023, which is at least fifteen (15) days prior to the date of the Annual General Meeting**. The request for the inclusion of any additional subjects at the daily agenda is accompanied by a justification or by a decision plan that has to be approved at the Annual General Meeting, and if the revised daily agenda is being published in any way like the previous daily agenda, on **the 13th.06.2023, which is at least thirteen (13) days before the date of the Annual General Meeting** and at the same time, it is published at the company's website, accompanied with the justification or the decision plan that has been submitted by the shareholders, according to article 123 par 4 of law 4548/2018.

(b) With an application from the shareholders that represent the one twentieth (1/20) of the paid-up shared capital, the company's Board of Directors sets at the shareholder's disposal based on article 123 par.3 of law 4548/2018, the latest until **20th.06.2023, which is at least six (6) days prior to the date of the Annual General Meeting,** the plans of decision making for the subjects that are included in the initial or the revised daily agenda, if the relevant application arrives at the Board of Directors until the **19th.06.2023, which is at least seven (7) days before the date of the Annual General Meeting.**

(c) After the application from any shareholder that is submitted at the company, **until the 20th.06.2023, which is at least last five (5) days prior to the date of the Annual General Meeting,** the Board of Directors is obligated to provide at the Annual General Meeting, the requested information on the Company's affairs, to the extent that they are relevant to the subjects under discussion on the daily agenda. There is no obligation to provide information that is already publicly available to the company's website, especially if this information is in the form of questions and answers.

Furthermore, with an application from the shareholders that represent the one twentieth (1/20) of the shared capital, the Board of Directors is obligated to announce at the Annual General Meeting, the amounts that they were paid over the last two years at every Board member or at the Company's directors, as well as any provision to these members due to any cause or contract of the company towards them. For all the aforementioned cases, the Board of Directors may refuse to provide the information due to substantial reason, that will be written on the agenda.

(d) If an application from the shareholders that represent the one tenth (1/10) of the paid - up shared capital, is submitted to the company until the **20th.06.2023, which is at least five (5) days prior to the Annual General Meeting,** the Board of Directors is obligated to provide at the Annual General Meeting, information about the course of corporate affairs as well as the financial state of the company.

The Board of Directors can deny the provision of information due to substantial reason that will be written on the agenda.

(e) With an application from the shareholders that represent the one twentieth (1/20) of the paid - up shared capital, the voting on a subject or on some subjects on the daily agenda, are conducted with an open vote.

For all the aforementioned cases, the requesting shareholders must prove their shareholder's status, apart from the first case of paragraph 6 of article 141 of law 4548/2018, the number of shares they hold at the time they proceed with the application. The proof of the shareholder's status can be provided by using any legal means and with the update that the company is receiving from the central securities depository, under the name "HELLENIC CENTRAL SECURITIES DEPOSITORY S.A", provided that it provides registry services, or through the participants or registered intermediaries at the central securities repository.

C. THE PROCESS FOR EXERCISING THE VOTING RIGHT THROUGH A REPRESENTATIVE

Each shareholder participates at the Annual General Meeting and votes either in person or through a representative. Every shareholder can appoint up to three (3) representatives. Legal entities can participate in the Annual General Meeting can appoint up to three (3) representatives. However, If the shareholder holds company shares, that appear to more than one securities account, this restriction is not an obstacle for the shareholder to appoint different representatives for the shares that appear in each account in the relation with the Annual General Meeting. A proxy holder acting for several shareholders may vote differently for each shareholder.

The representative is obligated to inform the company, prior to the beginning of the Annual General Meeting, of any specific fact that can be useful for the shareholders to assess the risk of serving other interests to the ones of the shareholder they represent. From this paragraph, a conflict of interest may arise especially if the representative:

(a) is a shareholder that exercises the control of the company, or is any other legal entity whom is being controlled by this shareholder,

(b) is a member of the Board of Directors, or a manager of the company or a shareholder that exercises the control of the company or any other legal entity that is being controlled from the shareholder whom has the company's control.

(c) is an employee or an auditor of the company or the shareholder that exercises the control of the company or any other legal entity that is being controlled by the shareholder whom has the company's control.

(d) is a spouse or a first degree relative with one of the cases mentioned in (a) through (c).

The appointment, or the revoke, or the replacement of the shareholders' representative should be made in writing and submitted to the company, at least forty-eight (48) before the date of the Annual General Meeting.

The company has made the application of the appointment of a representative, publicly available through its website (www.mediconsa.com). This application should be filled out, signed and then delivered by the shareholder to the company's Shareholders Service Department, at Gerakas Attikis, at the address Melitona 5 – 7, or should be sent by fax 210 – 6612666, at least forty-eight (48) prior to the date of the Annual General Meeting.

It is the shareholder's responsibility to confirm the application has been received and processed by calling during working hours on the number 210 – 6606129.

D. AVAILABLE DOCUMENTS

The full script of the decisions and of any documents that are provided in article 123 par.4 of law 4548/2018 will be available in printed documents at the company's premises (Gerakas Attikis, Melitona 5-7).

E. AVAILABLE INFORMATION

The information from par.3 and 4 of article 123 of law 4548/2018 will be available in digital form at the company's webpage www.mediconsa.com.

Gerakas Attikis, 2 June 2023

Upon order from the Board of Directors

THE PRESIDENT OF B.O.D AND C.E.O

SPYRIDON DIMOTSANTOS